Colleen Kelly explores FMT for Crohn’s disease and severe obesity
- Fecal microbiota transplantation (FMT) and inflammatory bowel disease (IBD) management intersect in ongoing clinical research and patient care led by specialists like Colleen Kelly, MD, a gastroenterologist at...
- Current FDA-approved FMT products are indicated specifically for the prevention of recurrent CDI, leaving a critical therapeutic gap for acute, severe, or fulminant CDI cases where patients are...
- Medical assumptions regarding inflammatory bowel disease have traditionally associated the condition with severe thinness and malnourishment, but modern clinical practice reveals that obesity prevalence in IBD patients closely...
Fecal microbiota transplantation (FMT) and inflammatory bowel disease (IBD) management intersect in ongoing clinical research and patient care led by specialists like Colleen Kelly, MD, a gastroenterologist at Brigham and Women’s Hospital and faculty member at Harvard Medical School in Boston. While two FDA-approved FMT products have largely replaced conventional stool transplantation for preventing recurrent Clostridioides difficile infection (CDI), researchers are actively exploring how microbiome-based therapies might address other dysbiosis-driven conditions such as Crohn’s disease and severe obesity.
Advancements and Regulatory Challenges in Fecal Microbiota Transplantation
Current FDA-approved FMT products are indicated specifically for the prevention of recurrent CDI, leaving a critical therapeutic gap for acute, severe, or fulminant CDI cases where patients are septic and often require multiple doses in intensive care units. According to Kelly, conducting placebo-controlled clinical trials in such critically ill populations presents significant ethical hurdles. To gather real-world safety and effectiveness data, investigators are utilizing the FMT National Patient Registry. Meanwhile, institutions like Brigham and Women’s Crohn’s and Colitis Center are collaborating with researchers such as Alexander Khoruts, MD, one of the original pioneers of stool banking, to investigate whether open-label FMT protocols can positively alter the disease course in Crohn’s disease patients.
Clinical Complexities at the Intersection of Obesity and IBD
Medical assumptions regarding inflammatory bowel disease have traditionally associated the condition with severe thinness and malnourishment, but modern clinical practice reveals that obesity prevalence in IBD patients closely mirrors the general United States population. Treating patients who present with both severe obesity and complex gastrointestinal disorders introduces intense clinical challenges. Kelly, who serves as a diplomate of the American Board of Obesity Medicine, highlights instances involving patients with extraordinarily high body mass indexes, concurrent cutaneous Crohn’s, total proctocolectomies with ileostomies, and poorly controlled diabetes who experience no meaningful weight loss response even from high doses of newer medications like tirzepatide, leaving bariatric surgery as a primary yet often intimidating option.
Patient Selection and Future Research Directions
Expanding clinical trials evaluating microbiome therapies for IBD involves rigorous screening and steady prospective patient tracking. Enrollment requirements dictate that participants maintain stable underlying therapies, a criterion that can slow recruitment because individuals undergoing acute IBD flares cannot wait or may feel reluctant to enter a structured research study. As investigators continue to collect data through open-label trials and nationwide registries, the medical community balances high expectations for microbiome manipulation against the immediate, complex bedside needs of patients living with overlapping metabolic and gastrointestinal diseases.